Back to search

Article

Explorative analysis of a predictive score for patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with [177Lu]Lu-labeled prostate-specific membrane antigen

2020-04-27

Abstract excerpt

<title>Abstract</title> <p>Background: Up to 60% of patients with metastatic, castration-resistant prostate cancer (mCRPC) treated with [177Lu]Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) achieve partial biochemical response with a decrease of >50% in prostate-specific antigen (PSA) levels. The remaining fraction of patients, however, do not respond to RLT. The aim of this explor...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f2a1e39e-215f-5683-bee7-187e4392b723
DOI
10.21203/rs.3.rs-24704/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Explorative analysis of a predictive score for patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with [177Lu]Lu-labeled prostate-specific membrane antigenDOI 10.21203/rs.3.rs-24704/v1
Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand Therapy.Semantic proximity
Dual-Tracer 18 F-FDG and 68 Ga-PSMA PET/CT Imaging of Heterogeneous Phenotypes of Metastatic Castration-Resistant Prostate Cancer for Predicting Response to Novel Hormone Therapy.Semantic proximity
Patterns of disease detection using 18F-DCFPyL PET/CT imaging in men with biochemical recurrence post prostatectomy being considered for salvage radiotherapy: a prospective trialSemantic proximity
How the Management of Biochemical Recurrence in Prostate Cancer Will be Modified by the Concept of Anticipation and Incrementation of TherapySemantic proximity
Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and <i>in silico</i> trialsSemantic proximity
Simplified Predictive Nomogram for Postprostatectomy Patients Treated with High-dose Salvage Intensity Modulated Radiation TherapySemantic proximity
Bone Pain Is Associated with Short Radiologic-Progression-Free Survival in Patients with Metastatic Castration-Sensitive Prostate CancerSemantic proximity
Early PSA Decline after Starting Second-Generation Hormone Therapy in the Post-Docetaxel Setting Predicts Cancer-Specific Survival in Metastatic Castrate-Resistant Prostate CancerSemantic proximity
Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysisSemantic proximity
Dual-tracer PET/CT identifies an aggressive PSMA-negative/FDG-positive phenotype predicting early failure of radical prostatectomy in treatment-naive prostate cancer.Semantic proximity
Simplified Predictive Nomogram for Postprostatectomy Patients Treated with High-dose Salvage Intensity Modulated Radiation TherapySemantic proximity
Reliability of Prostate Imaging Reporting and Data System Version 2.1 for Excluding Clinically Significant Prostate Cancer Using a 1.5 Tesla ScannerSemantic proximity
Select a neighboring publication to make it the new centre.